Search

Your search keyword '"Jeffrey, Schlom"' showing total 851 results

Search Constraints

Start Over You searched for: Author "Jeffrey, Schlom" Remove constraint Author: "Jeffrey, Schlom"
851 results on '"Jeffrey, Schlom"'

Search Results

53. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

54. Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management

55. A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer

56. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

57. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

58. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

59. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer

60. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist

61. Overcoming hypoxia-induced functional suppression of NK cells

62. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations

63. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine

64. The Use of a Humanized NSG-β2m−/− Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa

65. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

66. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies

68. Phase 1 trial of <scp>CV301</scp> in combination with <scp>anti‐PD</scp> ‐1 therapy in <scp>nonsquamous non‐small</scp> cell lung cancer

69. The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex

70. Exploiting docetaxel-induced tumor cell necrosis with tumor targeted delivery of IL-12

71. Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer

72. Supplementary Data from Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy

74. Data from Therapy of Established Tumors with Rationally Designed Multiple Agents Targeting Diverse Immune–Tumor Interactions: Engage, Expand, Enable

75. Data from Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy

76. Supplementary Figure 1 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

78. Data from Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor

79. Data from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

81. Supplementary Figures 1 through 3 and Supplementary Tables 1 through 3 from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

82. Supplemental Figure 1 from Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury

83. Data from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

88. Supplementary Tables 1 - 2 from Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

90. Data from Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer

94. Data from Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy

95. A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

96. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)

98. Supplementary Figure S7 from Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models

99. Supplementary Data from Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

100. Data from Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Catalog

Books, media, physical & digital resources